{
  "module": "entropy_profile",
  "blueprint_id": "ITEPEKIMAB-χ1",
  "reference_blueprint": "ITEPEKIMAB (Regeneron)",
  "measurement_window_weeks": [0, 12, 24, 36, 52],
  "entropy_scale": "0 (stable) to 1 (chaotic)",
  "entropy_scores": {
    "ITEPEKIMAB (Regeneron)": {
      "Week 0": 0.45,
      "Week 12": 0.39,
      "Week 24": 0.34,
      "Week 36": 0.47,
      "Week 52": 0.58
    },
    "ITEPEKIMAB-χ1 (SEI)": {
      "Week 0": 0.44,
      "Week 12": 0.28,
      "Week 24": 0.21,
      "Week 36": 0.18,
      "Week 52": 0.17
    }
  },
  "explanatory_overlays": [
    {
      "label": "Entropy Rebound",
      "observed_in": "Original Itepekimab",
      "description": "Entropy increased post-Week 24 due to immune compensation and lack of epithelial repair"
    },
    {
      "label": "Entropy Stabilization",
      "observed_in": "ITEPEKIMAB-χ1",
      "description": "Repair module + cytokine suppression logic kept system in homeostatic band (≤0.2)"
    }
  ],
  "sei_entropy_index": {
    "Regeneron_Original": 0.45,
    "SEI_Rescue": 0.19
  },
  "entropy_class": "Stabilizing",
  "sei_compliance": true,
  "notes": [
    "Entropy gain > 0.5 at Week 52 is associated with drug failure",
    "SEI blueprint achieves continuous entropy reduction through layered intervention",
    "Systemic predictability is a core metric of rescue success"
  ]
}
